Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 15

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 15
---
 Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. He later became the first physician in Brazil to treat Gaucher disease using enzyme replacement therapy. In addition, Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro. Dr. Vivaldi’s experience as an executive officer in the life sciences industry and his extensive pharmaceutical commercialization and marketing experience with several different companies contributed to our board of directors’ conclusion that he should serve as a director of our company. Members of the Board of Directors Continuing in Office Term Expiring at the 2026 Annual Meeting of Stockholders (Class II)

| Name                    |     | Age |     | Present Position with Crinetics Pharmaceuticals, Inc. |
| Caren Deardorf          |     |  60 |     | Director                                              |
| Weston Nichols, Ph.D.   |     |  40 |     | Director                                              |
| Stephanie S. Okey, M.S. |     |  65 |     | Director                                              |

<div align='center'>9</div>

Caren Deardorf has served on our board of directors since March 2022. Ms. Deardorf most recently served as Chief Commercial & Strategy Officer at Editas Medicine from September 2023 until April 2025, responsible for commercial and corporate strategy for the pipeline and program leadership. Previously, she served as the Chief Commercial Officer of Magenta Therapeutics, Inc., where she was responsible for the strategy, direction and execution of Magenta’s global commercial capabilities, a position she held from July 2021 until March 2023. Ms. Deardorf was Chief Commercial Officer of Ohana Biosciences from May 2019 to May 2021 and Vice President of global product development at Biogen from 2017 to 2019, where she was the commercial lead on Spinraza®, a treatment for children and adults with spinal muscular atrophy, a rare and often fatal inherited disease that typically presents in infancy. In this role, she led the development of the global launch strategy including commercial footprint, branding and reimbursement strategies. Earlier in her career at Biogen, Ms. Deardorf was part of the building of the MS franchise of global brands—AVONEX® and TYSABRI®—and was responsible for brand strategy and global launch for Tecfidera, a treatment for relapsing forms of multiple sclerosis. Ms. Deardorf served